MaxCyte has entered a strategic platform licence with US biotech Moonlight Bio to support the development of engineered T cell therapies for solid tumours.

The deal grants Moonlight Bio non-exclusive rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform for research, clinical and commercial applications. In return, MaxCyte will receive annual licence fees and programme-related revenue.

The agreement extends MaxCyte’s network of cell and gene therapy collaborators and supports Moonlight Bio’s efforts to progress its preclinical T cell therapy pipeline.

Maher Masoud, president and CEO of MaxCyte, said: “We’re proud to partner with Moonlight Bio as they advance their gene-edited cell therapies through clinical development. Our ExPERT platform is built to accelerate manufacturing and enable scalable cell engineering.”

Moonlight Bio, based in Seattle, Washington, is developing gene-edited T cell therapies designed to improve efficacy in solid tumours. Jordan Jarjour, chief scientific officer of Moonlight Bio, said: “We look forward to collaborating with MaxCyte and leveraging their GMP-compliant electroporation technology and scientific expertise to build our clinical manufacturing process.”

He added: “At Moonlight Bio, we are committed to delivering T cell therapies that overcome the barriers to success in solid tumours, which account for the majority of the global cancer burden.”

The collaboration underlines continued investment in cell-engineering technologies aimed at improving gene delivery efficiency and scalability in complex manufacturing environments.